FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158895086> ?p ?o ?g. }

• W2158895086 abstract "Novel strategies are being applied for creating better in vitro models that simulate in vivo conditions for testing the efficacy of anticancer drugs. In the present study we developed surface-engineered, large and porous, biodegradable, polymeric microparticles as a scaffold for three dimensional (3-D) growth of a Y79 retinoblastoma (RB) cell line. We evaluated the effect of three anticancer drugs in naïve and nanoparticle-loaded forms on a 3-D versus a two-dimensional (2-D) model. We also studied the influence of microparticles on extracellular matrix (ECM) synthesis and whole genome miRNA-gene expression profiling to identify 3D-responsive genes that are implicated in oncogenesis in RB cells.Poly(D,L)-lactide-co-glycolide (PLGA) microparticles were prepared by the solvent evaporation method. RB cell line Y79 was grown alone or with PLGA-gelatin microparticles. Antiproliferative activity, drug diffusion, and cellular uptake were studied by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole (MTT) assay, fluorescent microscope, and flow cytometry. Extra cellular matrix (ECM) synthesis was observed by collagenase assay and whole genome miRNA-microarray profiling by using an Agilent chip.With optimized composition of microparticles and cell culture conditions, an eightfold increase from the seeding density was achieved in 5 days of culture. The antiproliferative effect of the drugs in the 3-D model was significantly lower than in the 2-D suspension, which was evident from the 4.5 to 21.8 fold differences in their IC(50) values. Using doxorubicin, the flow cytometry data demonstrated a 4.4 fold lower drug accumulation in the cells grown in the 3-D model at 4 h. The collagen content of the cells grown in the 3-D model was 2.3 fold greater than that of the cells grown in the 2-D model, suggesting greater synthesis of the extracellular matrix in the 3-D model as the extracellular matrix acted as a barrier to drug diffusion. The microarray and miRNA analysis showed changes in several genes and miRNA expression in cells grown in the 3-D model, which could also influence the environment and drug effects.Our 3-D retinoblastoma model could be used in developing effective drugs based on a better understanding of the role of chemical, biologic, and physical parameters in the process of drug diffusion through the tumor mass, drug retention, and therapeutic outcome." @default.
• W2158895086 created "2016-06-24" @default.
• W2158895086 creator A5027734512 @default.
• W2158895086 creator A5035974651 @default.
• W2158895086 creator A5054208754 @default.
• W2158895086 creator A5061368317 @default.
• W2158895086 creator A5072272304 @default.
• W2158895086 creator A5083511568 @default.
• W2158895086 date "2012-01-01" @default.
• W2158895086 modified "2023-09-29" @default.
• W2158895086 title "A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs." @default.
• W2158895086 cites W1562907760 @default.
• W2158895086 cites W1576300062 @default.
• W2158895086 cites W1648301895 @default.
• W2158895086 cites W1964976936 @default.
• W2158895086 cites W1967120404 @default.
• W2158895086 cites W1968422706 @default.
• W2158895086 cites W1971117609 @default.
• W2158895086 cites W1979847047 @default.
• W2158895086 cites W1982995250 @default.
• W2158895086 cites W1989908520 @default.
• W2158895086 cites W1992598298 @default.
• W2158895086 cites W1993418575 @default.
• W2158895086 cites W2002072986 @default.
• W2158895086 cites W2005286647 @default.
• W2158895086 cites W2013993442 @default.
• W2158895086 cites W2014900267 @default.
• W2158895086 cites W2019866887 @default.
• W2158895086 cites W2032461554 @default.
• W2158895086 cites W2032541751 @default.
• W2158895086 cites W2033363278 @default.
• W2158895086 cites W2033595939 @default.
• W2158895086 cites W2034203463 @default.
• W2158895086 cites W2035796112 @default.
• W2158895086 cites W2036224487 @default.
• W2158895086 cites W2038135541 @default.
• W2158895086 cites W2047076998 @default.
• W2158895086 cites W2047529648 @default.
• W2158895086 cites W2049230955 @default.
• W2158895086 cites W2051090208 @default.
• W2158895086 cites W2053067121 @default.
• W2158895086 cites W2058153577 @default.
• W2158895086 cites W2059766794 @default.
• W2158895086 cites W2079142824 @default.
• W2158895086 cites W2091576301 @default.
• W2158895086 cites W2091800170 @default.
• W2158895086 cites W2094126824 @default.
• W2158895086 cites W2099052265 @default.
• W2158895086 cites W2111655556 @default.
• W2158895086 cites W2121296688 @default.
• W2158895086 cites W2127362646 @default.
• W2158895086 cites W2140474512 @default.
• W2158895086 cites W2143160815 @default.
• W2158895086 cites W2144701362 @default.
• W2158895086 cites W2155412740 @default.
• W2158895086 cites W2156368993 @default.
• W2158895086 cites W2168509670 @default.
• W2158895086 cites W2253959633 @default.
• W2158895086 cites W2411491700 @default.
• W2158895086 cites W68002579 @default.
• W2158895086 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3369889" @default.
• W2158895086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22690114" @default.
• W2158895086 hasPublicationYear "2012" @default.
• W2158895086 type Work @default.
• W2158895086 sameAs 2158895086 @default.
• W2158895086 citedByCount "21" @default.
• W2158895086 countsByYear W21588950862013 @default.
• W2158895086 countsByYear W21588950862015 @default.
• W2158895086 countsByYear W21588950862016 @default.
• W2158895086 countsByYear W21588950862017 @default.
• W2158895086 countsByYear W21588950862018 @default.
• W2158895086 countsByYear W21588950862019 @default.
• W2158895086 countsByYear W21588950862020 @default.
• W2158895086 countsByYear W21588950862021 @default.
• W2158895086 countsByYear W21588950862022 @default.
• W2158895086 countsByYear W21588950862023 @default.
• W2158895086 crossrefType "journal-article" @default.
• W2158895086 hasAuthorship W2158895086A5027734512 @default.
• W2158895086 hasAuthorship W2158895086A5035974651 @default.
• W2158895086 hasAuthorship W2158895086A5054208754 @default.
• W2158895086 hasAuthorship W2158895086A5061368317 @default.
• W2158895086 hasAuthorship W2158895086A5072272304 @default.
• W2158895086 hasAuthorship W2158895086A5083511568 @default.
• W2158895086 hasConcept C150903083 @default.
• W2158895086 hasConcept C153911025 @default.
• W2158895086 hasConcept C185592680 @default.
• W2158895086 hasConcept C202751555 @default.
• W2158895086 hasConcept C207001950 @default.
• W2158895086 hasConcept C2780165375 @default.
• W2158895086 hasConcept C54355233 @default.
• W2158895086 hasConcept C553184892 @default.
• W2158895086 hasConcept C55493867 @default.
• W2158895086 hasConcept C81885089 @default.
• W2158895086 hasConcept C86803240 @default.
• W2158895086 hasConceptScore W2158895086C150903083 @default.
• W2158895086 hasConceptScore W2158895086C153911025 @default.
• W2158895086 hasConceptScore W2158895086C185592680 @default.
• W2158895086 hasConceptScore W2158895086C202751555 @default.
• W2158895086 hasConceptScore W2158895086C207001950 @default.
• W2158895086 hasConceptScore W2158895086C2780165375 @default.

• next